HanchorBio dedicates to develop biological medicines with simultaneous multi-targeting through a novel IgG Fc-Based Designer Biologics (FBDB™) platform.
CULTURE
The culture of emphasis on innovation, quality, and speed will remain and be nourished
VISION
To be a pioneering biotech company that transforms innovative drug development with biologics having novel modalities.
MISSION
MISSION To transcend the Immuno-Oncology therapeutics by developing cutting-edge designer biologics with innovative modalities for cancer patients.
CORE VALUES
INNOVATION
INTEGRITY
EXECUTION
EXCELLENCE
ACCOUNTABILITY
TEAM WORK
LEADERSHIP TEAM
SCOTT LIU, PH.D.
Founder, Chairman & CEO of HanchorBioFounder, Chairman & CEO of HanchorBio
SCOTT LIU, PH.D.
- Co-Founder and ex-CEO of Henlius/Henlix/Hengenix, a commercial-stage biopharma. company listed on HK Stock Exchange with a valuation of ~US$3 Billion
- 12-years experience in corporate developmet & management, strategic planning, fundraising & BD,… etc.; led Henlius from a start-up biotech to a top biopharma in China, with 3 commercial mAb products lunched in China and EU
- 30-year experiences in biotech R&D, cGMP quality operation and management, CMC & clinical regulatory affairs, portfolio management etc.
- Led Henlius teams in development of >30 biosimilars, novel mAbs and bsAbs, and combo immunotherapies.
- Development of multiple biologic products from research to launch, including Orencia® (for rheumatoid arthritis), Vectibix®(for colorectal cancer), Hanlikang® (Rituxan biosimilar, for lymphoma), Hanquyou®/Zercepac® ( Herceptin biosimilar, for breast & gastric cancers), and Handayuan (Humira biosimilar for autoimmune diseases)
- Director, Quality Analytical Laboratories, Amgen (Fremont, CA) (now B.I.)
- Associate Director, Biologics QC, Bristol-Myers Squibb (Syracuse, NY)
- VP, Scientific Affairs, United Biomedical Inc. (Happauge, NY)
- Ph.D. in biology at Purdue University and postdoc at Stanford University
SEAN JUO, PH.D.
General Manager & Chief Scientific OfficerGeneral Manager & Chief Scientific Officer
SEAN JUO, PH.D.
- Proven record of success from prominent pharmaceutical/biotech companies and academic institutions including Yale University, Stanford University/Howard Hughes Medical Institute, Pfizer Global Biotherapeutic Technologies/Biomedicine Design and Dragonfly Therapeutics
- Specialized in novel protein design, antibody engineering, and therapeutic platform innovation through broad-based expertise in structure-guided protein modeling, protein biochemistry, molecular/cellular biology, and assay development
- Director of Protein and Cytokine Engineering to lead scientists at Dragonfly Therapeutics on unique cytokine programs (2019-2020)
- Led the protein/cytokine engineering efforts in Dragonfly and participated in the molecular designs of several programs (DF9000, DF6000, DF6100, and DF6200). The lead molecule of the DF6000 program (engineered IL-12) was licensed to BMS for US$475 million near-term payment and substantial milestone-based royalties.
- Principal Scientist in Biomedicine Design at PFIZER, INC. (2009-2019)
- Research Specialist in Garcia laboratory of Howard Hughes Medical Institute at STANFORD UNIVERSITY (2005-2009)
- Associate Res. Scientist & Resident Fellow at Branford College, YALE UNIVERSITY (2000-2005)
- Postdoctoral associate in the Department of Molecular Biophysics & Biochemistry at YALE UNIVERSITY SCHOOL OF MEDICINE (1996-1999)
- Ph.D. degree in Biochemistry at UNIVERSITY OF CALIFORNIA LOS ANGELES (1996)
Yuehua Cong, Ph.D.
Chief Business OfficerChief Business Officer
Yuehua Cong, Ph.D.
- VP of Business Development for Europe/UK at Simcere Pharmaceutical Group, responsible for in-licensing and out-licensing.
- Head of Business Development at F-star Biotechnology where he completed several major licensing agreements.
- Head of Business Development & Scientific Liaison and Head of Chemistry Department at PolyTherics Ltd.
- Dr. Cong has extensive business development and investment experience in life sciences; is proficient in applying international partnership models with excellent track records of in-licensing and out-licensing; has entrepreneurial experience in company building; possesses multidisciplinary scientific background coupled with visionary leadership and teamwork abilities.
- PhD in Organic Chemistry, University of Konstanz, Germany
- MSc in Environmental Quality and Safety, University of Magdeburg, Germany
- MEng in Chemical Engineering, Northeastern University, China
Jason Tsai, M.D., M.S.
Chief Medical OfficerChief Medical Officer
Jason Tsai, M.D., M.S.
- Led pre-clinical/PhI, II, III development strategy/protocol design/execution for 7 small/large molecules, with successful pivotal PhIII in advanced ER+ breast cancer; raised $70+MM series C & led clinical co-development strategy of Epertinib with Shionogi
- Led medical affairs data generation/communication/MSL strategy & teams for CREON - $840MM+/year complex biologics replacement therapy – in cystic fibrosis, pancreatic resection, chronic pancreatitis, pancreatic cancer, and diabetes
- Provided consulting services for biotech/medical device companies with indication/development strategy, trial design, translational medicine, and product medical strategy
- Postdoctoral fellow, Stanford University School of Medicine; Wuerzburg University Dpt of Biophysics
- M.D., USC Keck School of Medicine
- M.S., Physiology & Biophysics, Cornell University/Sloan Kettering Cancer Center
CHI-LING TSENG, PH.D.
VP of ResearchVP of Research
CHI-LING TSENG, PH.D.
- >12 yr. experiences in discovery research of innovative biologics (Abs & vaccines)
- Senior Scientist, Director and Senior Director of Henlix (Henlius-TW)
- Led Henlix’s research team (28~30 Scientists) on target selection & validation, in vitro/in vivo pharmacology analysis, and PK/PD assays
- Participated in IND-enabling PD studies of over 14 mAb products
- The inventor of 9 patents (2 for cancer vaccines and 7 for therapeutic Abs)
- Ph.D. in Biochemistry and Molecular Biology at the National Yang Ming University and postdoc at Vaccine Center of NHRI
- B.S. degree in Medical Technology and a licensed clinical laboratory scientist
WEIDONG JIANG, PH.D.
Director of the Board, HanchorBioDirector of the Board, HanchorBio
WEIDONG JIANG, PH.D.
- Co-Founder and CSO at Henlius/Henlix/Hengenix, a commercial-stage biopharma. company listed on HK Stock Exchange with a valuation of ~US$3 Billion
- Over 25 yr. experiences in biologics drug discovery and development
- Led Henlius teams in development of >30 biosimilars, novel mAbs and bsAbs, and combo immunotherapies.
- Development of multiple biologic products from research to launch, including Orencia® (for rheumatoid arthritis), Vectibix®(for colorectal cancer), Hanlikang® (Rituxan biosimilar, for lymphoma), Hanquyou®/Zercepac® ( Herceptin biosimilar, for breast & gastric cancers), and Handayuan (Humira biosimilar for autoimmune diseases)
- Director/Group leader in Vasgene Therapeutics, Applied Molecular Evolution (Lilly), ChemGenics, Microcide and Catalyst Biosciences
- Ph. D. in biology at University of Giessen Germany and postdoc at University of California
AUDREY TSENG, M.B.A.
Director of the BoardDirector of the Board
AUDREY TSENG, M.B.A.
- Current Positions
- Honorary Deputy Chairman of PwC Taiwan
- Adjunct Professor of National Chengchi University
- Managing Supervisor of Taiwan Bio-industry Organization
- Managing Supervisor of Precision Medicine & Molecular Diagnostics Industry Association of Taiwan
- Director, Taipei Biotech Association
- Supervisor of Food Industry Research and Development Institute
- Supervisor of Medical and Pharmaceutical Industry Technology and Development Centre
- Member of various review committees for competitions, funding plans, and investment plans, both held by governments and private entities
- >30 years of experience in Taiwan-licensed CPA, including Taiwan Stock Exchange, Delta Electronics, Asustek, Foxconn, WPG Holdings and TECO.
- >20 years of assisted experience in many biopharma and medtech companies to list in Taiwan, including BIONET, Formosa Laboratories, PharmaEngine, OBI Pharma, Taiwan Lipsome, TWI Pharma, Crown Bioscience, Senhwa Biosciences, Tanvex BioPharma, Lumosa Therapeutics, Foresee Pharmaceutical , EirGenix, Medeon Biodesign, CHC Healthcare Group, Onxy Healthcare, Taiwan Biomaterial and Applied Biocode Corporation, etc.
- Specialized in multinational financial and tax planning, M&A, corporate governance, industrial development and business strategies.
- Extensive overseas IPO advisory experiences, including Tom.com, Delta Networks, TOT Biopharma’s IPO in Hong Kong and Taiwan Liposome Company’s ADR issuance in the U.S.
- Provide dedicated IPO consulting services for companies intending to register on China A-shares and Sci-Tech Innovation Board.
- MBA in business administration at National Taiwan University and Fudan University.
- MBA in accounting at National ChengChi Unversity